Mesothelioma research | Cancer Research UK
Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter

Mesothelioma research

Men and women discussing mesothelioma

This page is about research into mesothelioma causes, prevention and treatments. You can use these links to go straight to sections about


A quick guide to what's on this page

Mesothelioma research

All treatments must be fully researched before they can be adopted as standard treatment for everyone. This is so that we can be sure they work better than the treatments we already use. And so we know they are safe. First of all, treatments are developed and tested in laboratories. Only after we know that they are likely to be safe to test are they tested in people, in clinical trials. Cancer Research UK supports a lot of UK laboratory research into cancer and also supports many UK and international clinical trials.

Researchers are looking into


CR PDF Icon You can view and print the quick guides for all the pages in the Treating mesothelioma section.



Why we need research

All treatments have to be fully researched before they can be adopted as standard treatment for everyone. This is so that

  • We can be sure they work
  • We can be sure they work better than the treatments that are available at the moment
  • They are known to be safe

First of all, treatments are developed and tested in laboratories. For ethical and safety reasons, experimental treatments must be tested in the laboratory before they can be tried in patients. If a treatment described here is said to be at the laboratory stage of research, it is not ready for patients and is not available either within or outside the NHS. Cancer Research UK supports a lot of UK laboratory research into cancer.

Tests in patients are called clinical trials. Cancer Research UK supports many UK and international clinical trials.

Our trials and research section has information about what trials are, including information about the 4 phases of clinical trials. If you are interested in taking part in a clinical trial, look at our clinical trials database. If there is a trial you are interested in, print it off and take it to your own specialist. If the trial is suitable for you, your doctor will need to make the referral to the research team. The database also has information about closed trials and trial results.

All the new approaches covered here are the subject of ongoing research. Mesothelioma is one of the hardest types of cancers to treat. Progress has been made in treating this type of cancer. But we need to learn a lot more about this disease and how best to treat it.

Until research studies are completed and new effective treatments are found, the treatments covered here cannot be used as standard therapy for mesothelioma.

Here is a video on experiences of taking part in a clinical trial:

View a transcript of the video (Opens in a new window)


Causes and prevention

Many cases of mesothelioma are caused by exposure to asbestos. In the past, asbestos was used widely in the

  • Building industry
  • Ship building industry
  • Manufacture of household appliances
  • Motor industry
  • Power stations
  • Telephone exchanges

The MALCS study confirmed that people who worked in jobs with high levels of exposure to asbestos have an increased lifetime risk of developing mesothelioma or lung cancer. The researchers also found an increased risk in men and women who lived with an exposed worker before the age of 30. 

You can read the results of the MALCS study on our clinical trials database.

Asbestos use has been banned in the UK for a number of years, but many buildings still contain it. Some asbestos is still in the air in certain workplaces, and everyone is exposed to small amounts in the outside air. The TIPS study aims to find out if people in the UK are still being exposed to asbestos. It is looking for fibres of asbestos in lung tissue samples from people who have had surgery for a collapsed lung (pneumothorax). 


Finding a tumour marker for mesothelioma

Mesothelioma can be very difficult to diagnose. This is because many different types of cells can develop into a mesothelioma tumour. Mesothelioma tumour cells are very similar to some types of lung cancer cells. Sometimes it can be very difficult for a pathologist to decide whether or not the cancerous cells are mesothelioma cells, lung cancer cells or even sarcoma cells.

To help with diagnosis, scientists are trying to find out whether particular chemicals are given off by mesothelioma cells that can be found in the blood and picked up in a blood test. These chemicals are called tumour markers. If a definite tumour marker could be discovered for mesothelioma this would help doctors to diagnose this disease more easily. Markers can also be helpful in monitoring how well treatment is working.

Soluble mesothelin related protein (SMRP) and osteopontin are new markers that are being researched. Osteopontin levels are raised in many patients with mesothelioma. SMRP levels are also raised in many patients with mesothelioma. But SMRP is also raised in ovarian cancer. So, SMRP can be useful in finding peritoneal mesothelioma and ovarian cancer, but it does not help to distinguish between them. Recent studies suggest that SMRP levels at diagnosis may help to give an idea of prognosis or how well your treatment may be working. However more studies are needed to look at this. 

Useful tumour markers for diagnosing and monitoring mesothelioma in the abdomen are CA 125 and CA 15-3. Research is looking at how helpful these may be.

At present, all these markers are still being researched and are not routinely available to patients. However, there is potential for combining them to improve their effectiveness.



There is some evidence that your genetic make up could affect your risk of mesothelioma. As well as asbestos, exposure to a mineral called erionite is a risk factor. Researchers in Turkey found that in some families exposed to this mineral, everyone developed mesothelioma, and in others, no one developed it. They think that the families affected must have a gene that increases their risk. This could explain why some people who are exposed to asbestos do not develop mesothelioma, while others do. 

We need a lot more research to be done before we will know if there are specific gene changes that can increase your risk of mesothelioma. It will be some years after this has been completed before there will be any chance of testing for such a gene.

Understanding the changes in the genes of the mesothelioma cells helps in developing treatments. Researchers are finding out more about these changes.  The aim of this research is to understand more about how mesothelioma develops and how the changes in the genes of the cancer cells affects how well different treatments work. They hope that this will help to guide treatment in the future.

In recent years, several gene mutations have been identified and found in patients with mesothelioma such as NF2 and BAP-1. Gene mutation testing is not performed routinely in mesothelioma. It may sometimes be performed as part of a clinical trial. You can search for open trials on our clinical trials database



It has been a major challenge for doctors to find chemotherapy drugs that work well in treating mesothelioma. Many trials have been done. The most commonly used combination of chemotherapy drugs for mesothelioma in the chest is currently pemetrexed and cisplatin or raltitrexed and cisplatin. Sometimes pemetrexed is combined with carboplatin. Other drugs being looked at in trials include

A trial called MS-01 compared the following treatments

  • Active symptom control (ASC)
  • ASC and vinorelbine
  • ASC, mitomycin, vinblastine and cisplatin (MVP)

The trial found that the combination chemotherapy MVP is no better than active symptom control but that vinorelbine on its own may control symptoms better and could possibly help people to live longer. More research is needed to be sure. Another trial looked at irinotecan, cisplatin and mitomycin (IPM). The results were encouraging, but more research is needed.

Onconase (ranpirnase) is an experimental chemotherapy drug, made from leopard frog eggs. It is not available in the UK. We have included it here because you may come across information about it on the web. A phase 3 clinical trial has been going on in the USA and Germany comparing Onconase and doxorubicin with doxorubicin alone for people with mesothelioma. The results seem to show that adding onconase to doxorubicin helped some people to live longer. Studies may now also look at combining onconase with other treatments.

Cisplatin and pemetrexed is the most common combination of chemotherapy given into a vein for abdominal mesothelioma but trials are testing the following drugs – irinotecan, cyclophosphamide, doxorubicin, dacarbazine and gemcitabine. Doctors are also using chemotherapy into the abdomen after surgery to try to control abdominal mesothelioma. There is detailed information about this on our chemotherapy for mesothelioma page.

Topotecan and irinotecan have not worked well at controlling mesothelioma when given by themselves. But in combination with other drugs, there have been some good results. There is information about the side effects of all the drugs mentioned above in the cancer drugs section.



In pleural mesothelioma, fluid can collect inside the chest. This makes it more difficult for your lung to expand and so it is harder to breathe. This is called a pleural effusion. It is usual to treat the pleural effusion by draining off the fluid and 'sticking' the pleura together. Doctors do this by putting in some sort of irritant, usually BCG vaccine, sterile talc or chemotherapy. This is called pleurodesis

The MesoVATS trial compared talc pleurodesis with an operation to remove part of the membrane around the lungs (video assisted thorascopic partial pleurectomy, or a VAT-PP). The researchers found that there was no difference between the 2 groups in the average length of time people lived after joining the trial (overall survival). But the people who had VAT-PP rated their quality of life higher than those who had talc pleurodesis at 6 and 12 months after the procedure. The VAT-PP cost more then talc pleurodesis, and resulted in longer hospital stays with more side effects. 

You can read more about the MesoVATS trial and the results

The TIME3 trial is looking at using a drug called urokinase to help drain fluid from around the lung to make breathing easier. Sometimes there is more than 1 pocket of fluid between the lung and chest wall. This makes it difficult to drain all the fluid away. Urokinase may help to break down the pockets. The aim of the trial is to see if urokinase can help control and improve shortness of breath caused by pleural effusion and improve the success rate of pleurodesis. This trial has now closed and we are waiting for the results.



Advances have been made in surgery for mesothelioma over the past few years. Not many people with mesothelioma are fit enough to get through a very large operation. But research has shown that some people can live longer after surgery to remove the pleural tumour on the affected side (either pleurectomy, decortication or extrapleural pneumonectomy), followed by chemotherapy or radiotherapy. Research is continuing to look into this intensive treatment because there is a risk of dying during such major surgery.

The MARS trial looked at the benefits and risks of extrapleural pneumonectomy (EPP) for people with mesothelioma who had had chemotherapy. Results from some studies in the USA suggest that giving a course of radiotherapy after the EPP helps to keep the disease under control for even longer. Some patients in the MARS trial had an EPP operation combined with radical radiotherapy. Others had other treatments, such as radiotherapy, chemotherapy, or less major surgery. The trial found that for most people EPP did not help them to live longer. Many people also had poorer quality of life after this type of surgery. 

You can find results of the MARS trial on our clinical trials database.

The MARS2 trial aims to compare surgery and chemotherapy with chemotherapy alone for people with mesothelioma affecting one side of their chest. The researchers want to find out whether the combination of treatment helps people to live longer and improves quality of life. The researchers need to find out first if it's possible to do a trial comparing these treatments. This is called a feasibility study.



Some people with mesothelioma have radiotherapy to the area where they have had tissue samples taken (biopsies) through the skin of the chest or had fluid drained from the chest. This aims to stop mesothelioma cells growing in scar tissue. Doctors do this as soon after the procedure as possible. But some recent studies have shown that this may not reduce the chances of mesothelioma spreading to the chest wall.

The PIT trial is looking at whether treating the wound from your mesothelioma tests with radiotherapy helps to prevent or delay small cancer growths (nodules) developing in that area. You can read more about the PIT trial. This trial has now closed and we are waiting for the results.

The SMART trial is looking at the best time to give radiotherapy to prevent mesothelioma spreading after a procedure to the chest wall. The doctors are also looking at the side effects of giving radiotherapy soon after a procedure and how it affects quality of life. This trial has now closed and we are waiting for the results.

There is a newer type of radiotherapy called Intensity Modulated Radiotherapy, or IMRT for short. IMRT allows the radiotherapy beams to be shaped more accurately and so may avoid more of the surrounding normal tissue. So, you may have fewer side effects. Researchers in America are looking into how well this works for mesothelioma after surgery to remove the pleura but it will be some time before the results will be available.


Biological therapy

Biological therapies use substances made naturally by the body to fight cancer. Some work by stopping tumours from being able to grow blood vessels. Others work by blocking chemical signals that tell cancer cells to grow. Some types directly damage cancer cells. Various biological therapy drugs are being tried for mesothelioma. 

The MAPS trial

The MAPS trial looked at adding bevacizumab (Avastin) to the present standard chemotherapy treatment (cisplatin plus pemetrexed) as a first treatment for advanced pleural mesothelioma. The trial involved 448 patients from hospitals in France. It found that people survived about 2 months longer when bevacizumab was added to the chemotherapy (18.8 months compared to 16·1 months). 

There were more side effects in people who had bevacizumab in addition to the chemotherapy. The side effects included high blood pressure and blood clots in some people. The researchers recommend that bevacizumab is considered as a treatment alongside chemotherapy for people diagnosed with pleural mesothelioma. 

Current biological therapy trials

A new drug called Arenegyr (NGR-hTNF) has been tested in people who have already had chemotherapy for mesothelioma. In early trials the drug seemed to control the mesothelioma for a few months and increase survival rates. This drug will now be tested in phase 3 trials to see how well it works. 

Bortezomib (Velcade) is being used in trials on its own and in combination with cisplatin. And Cetuximab is being looked at in a phase 2 trial in combination with pemetrexed and cisplatin

The COMMAND trial is looking at a new drug called defactinib to treat pleural mesothelioma. The researchers are comparing defactinib with a dummy drug (placebo), and to see what effect it has on quality of life. This trial has now closed and we are waiting for the results.

Gene therapy

Gene therapy is a type of biological therapy. By studying how changes in genes make normal cells become cancerous, scientists aim to eventually develop gene therapy, where damaged genes in the cancer cells can be replaced with normal ones. One type of gene therapy research for mesothelioma involves a virus that has been modified in the laboratory. The virus is injected into the pleural space in your chest, where mesothelioma develops. The idea is that the virus infects the mesothelioma cells with a gene. The gene makes the cancer sensitive to a specific drug that will kill the mesothelioma cells. Research is focusing on how to get the virus into the cancer cells reliably. It will be a while before we will be able to see whether this will develop into a useful treatment. 

There is a trial looking at a virus called HSV1716. HSV1716 is a type of virus that infects cancer cells and kills them. The aim of this study is to find out how safe HSV1716 is to treat people with mesothelioma of the chest.

Read more about the HSV1716 trial for mesothelioma on our trials database.

Cancer vaccines

Researchers are also looking into developing a vaccination to treat mesothelioma. There are cells in your blood called dendritic cells. Their job is to help other cells in the immune system to recognise cells that are foreign to the body (such as bacteria and viruses). By altering the genes inside some of your dendritic cells, the researchers hope to make immune system cells called T cells recognise mesothelioma cells as foreign. 

To make the vaccine, the researchers take some dendritic cells from a sample of your blood. They grow more of these cells in the laboratory and then alter the genes inside them (gene therapy) so that they can make proteins usually made by mesothelioma cells. They then inject these changed dendritic cells back into your skin as a vaccine. The researchers hope that the dendritic cells will use their new proteins to help T cells recognise mesothelioma cells and kill them.  There are trials going on in Europe and America. There are no trials in the UK at the moment.

The SKOPOS trial is looking at a different type of cancer vaccine, called TroVax, alongside chemotherapy for pleural mesothelioma. Many mesothelioma cells carry a protein called 5T4. In this trial, researchers want to find out if TroVax helps the immune system to recognise 5T4 and attack the mesothelioma cells that carry this protein. This trial has now closed and we are waiting for the results.

Read more about biological therapies.


Photodynamic Therapy (PDT)

PDT is a treatment that is used for a few types of cancers. A drug called a photosensitising agent is injected into the bloodstream and absorbed by the body's cells. It is absorbed more by cancer cells than normal cells. The drug makes cells sensitive to light. When the area to be treated is exposed to laser light, the cells are killed.

PDT has to be combined with an operation to treat mesothelioma. This has been tried for early stage mesothelioma. The photosensitising drug is injected into your bloodstream a few days before surgery. During surgery, the surgeon then shines the laser light directly onto the pleura.

PDT has been shown to be a safe type of treatment with other types of cancer. But in phase 1 and phase 2 clinical trials for mesothelioma, there were some major complications on a few occasions and so doctors have not widely accepted this treatment. It is particularly likely to be risky when used with major surgery and this combination of treatments is not available in the UK. There are no claims that this treatment will cure anyone with mesothelioma. It is very experimental. We have included it here because it is something you may have read or heard about.


Quality of life

People living with mesothelioma may have physical and psychological symptoms which can affect their quality of life. Palliative care involves caring for your physical, emotional, psychological and spiritual needs. Researchers for the RESPECT-Meso study want to find out if giving specialist palliative care early in mesothelioma treatment can improve quality of life and wellbeing for people throughout the course of their illness. They also want to find out how this may improve the wellbeing of family or friends closest to them.

Rate this page:
Submit rating


Rated 5 out of 5 based on 8 votes
Rate this page
Rate this page for no comments box
Please enter feedback to continue submitting
Send feedback
Question about cancer? Contact our information nurse team

No Error

Updated: 8 December 2015